NeuroXess Raises US$96.6 Million to Advance Brain-Computer Interface Technology

Chinese medical-technology company NeuroXess completed a RMB 700 million (approximately US$96.6 million) Series B financing round on 28 October, led by institutional investors including SDIC Juli and Shenzhen Capital Group. The funding will support clinical trials, regulatory registration, manufacturing expansion and next-generation brain-computer interface development. The deal creates opportunities for clinical research organisations, medical-device manufacturers, regulatory consultants, hospital partners and healthcare technology suppliers.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.